Form 4: Pliant Therapeutics Executive Acquires Shares Following Performance Milestone

Mike Ouimette, General Counsel & Corp. Sec'y of Pliant Therapeutics, acquired 14,954 shares of common stock following the achievement of a performance milestone related to total shareholder return.

Summary

• On July 9, 2024, Mike Ouimette, General Counsel & Corp. Sec'y of Pliant Therapeutics, acquired 14,954 shares of common stock.
• The acquisition was a result of the vesting of performance-vested stock units granted on July 28, 2022.
• The vesting was contingent upon the achievement of pre-established performance criteria related to the company's total shareholder return relative to the Nasdaq Biotechnology Index.
• The Compensation Committee of the Issuer's Board of Directors certified the achievement of these performance criteria.
• Following the transaction, Ouimette directly owns 101,700 shares of Pliant Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects the achievement of performance targets, leading to the vesting of stock units. This suggests the company is progressing towards its goals.

Positives

• The vesting of performance-based stock units suggests that Pliant Therapeutics has met certain performance targets related to shareholder return.
• The achievement of performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index is a positive indicator.

Industry Context

This filing reflects standard executive compensation practices within the biotechnology industry, where performance-based equity awards are common to align management incentives with shareholder value creation.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded biotechnology companies.
• Companies like Gilead Sciences, Amgen, and Biogen also utilize performance-based equity awards to incentivize executives to achieve specific financial and strategic goals.
• The vesting criteria tied to the Nasdaq Biotechnology Index is a reasonable benchmark for measuring Pliant Therapeutics' relative performance.

Stakeholder Impact

• The vesting of performance-based stock units can positively impact shareholders by aligning management's interests with shareholder value creation.
• Employees may be motivated by the company's achievement of performance targets.

Key Dates